Regulation by Nitric Oxide of Endotoxin-Induced Tissue Factor and Plasminogen Activator Inhibitor-1 in Endothelial Cells

Summary

The increase in nitric oxide (NO) production in lipopolysaccharide (LPS)-induced sepsis is thought to contribute to the development of shock. However, NO could also play an antithrombotic role. Little is known about the modulating effect of NO on the endothelial overexpression and production of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) occurring in endotoxemia. We analyzed the effect of N(G)-nitro-L-arginine-methyl-ester (L-NAME), an inhibitor of NO synthases, and S-nitroso-N-acetyl-D,L-penicillamine (SNAP), a NO donor, on the expression and synthesis of TF and PAI-1 by LPS-challenged human umbilical vein endothelial cells (HUVEC): L-NAME enhanced the increase in TF mRNA and antigen levels (P <0.05) observed in LPS-treated HUVEC; SNAP down-regulated the LPSinduced TF increment (p <0.05). However, no effects of NO on regulation of the LPS-dependent increase in PAI-1 could be seen. Thus, NO could play an antithrombotic role in sepsis by down-regulating the endothelial overexpression and production of TF.

Keywords

HUVEC - Sepsis - Nitric oxide - Tissue factor - Plasminogen activator inhibitor-1

• References

• 1 Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001; 29: S21-7.
• 2 van Hinsbergh VW. The endothelium: vascular control of haemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95: 198-201.
• 3 Esmon CT. The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness. Crit Care 2001; 05: S7-12.
• 4 Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 1997; 39: 343-50.
• 5 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-6.
• 6 Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 1988; 18: 328-41.
• 7 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
• 8 Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999; 34: 879-86.
• 9 Thiemermann C. Nitric oxide and septic shock. Gen Pharmacol 1997; 29: 159-66.
• 10 Noci MV, Velasco F, López A, López-Pedrera R, Rodríguez M. The effect of exogenous nitric oxide on plasminogen activator inhibitor in experimentally induced endotoxemia. Fibrinolysis 1996; 10: 21-5.
• 11 Jaimes EA, del Castillo D, Rutherford MS, Raij L. Countervailing influence of tumor necrosis factor-alpha and nitric oxide in endotoxemia. J Am Soc Nephrol 2001; 12: 1204-10.
• 12 Zhou XJ, Laszik Z, Ni Z, Wang XQ, Brackett DJ, Lerner MR, Silva FG, Vaziri ND. Down-regulation of renal endothelial nitric oxide synthase expression in experimental glomerular thrombotic microangiopathy. Lab Invest 2000; 80: 1079-87.
• 13 Jourdain M, Tournoys A, Leroy X, Mangalaboyi J, Fourrier F, Goudemand J, Gosselin B, Vallet B, Chopin C. Effects of N omega-nitro-Larginine methyl ester on the endotoxin-induced disseminated intravascular coagulation in porcine septic shock. Crit Care Med 1997; 25: 452-9.
• 14 Harbrecht BG, Billiar TR, Stadler J, Demetris AJ, Ochoa J, Curran RD, Simmons RL. Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J Leukoc Biol 1992; 52: 390-4.
• 15 Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 1992; 90: 1718-25.
• 16 Westberg G, Shultz PJ, Raij L. Exogenous nitric oxide prevents endotoxininduced glomerular thrombosis in rats. Kidney Int 1994; 46: 711-6.
• 17 Gerlach M, Keh D, Bezold G, Spielmann S, Kurer I, Peter RU, Falke KJ, Gerlach H. Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite. Intensive Care Med 1998; 24: 1199-208.
• 18 Corseaux D, Le Tourneau T, Six I, Ezekowitz MD, Mc Fadden EP, Meurice T, Asseman P, Bauters C, Jude B. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: inhibition with dietary L-arginine. Circulation 1998; 98: 1776-82.
• 19 Minuz P, Degan M, Gaino S, Meneguzzi A, Zuliani V, Lechi CSantonastaso, Del Soldato P, Lechi A. NCX4016 (NO-aspirin) inhibits thromboxane biosynthesis and tissue factor expression and activity in human monocytes. Med Sci Monit 2001; 07: 573-7.
• 20 Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000; 101: 2144-8.
• 21 Bachetti T. L-arginine and nitric oxide: an inseparable couple?. Circulation 2001; 103: E57. (letter).
• 22 Jaffe EA, Nachmanm RL, Becker CG, Minick CR. Cultured of human endothelial cells derived from umbilical veins. Idenfication by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
• 23 Orbe J, Montes R, Zabalegui N, Pérez-Ruiz A, Páramo JA. Evidence that heparin but not hirudin reduces PAI-1 expression in cultured human endothelial cells. Thromb Res 1999; 94: 137-45.
• 24 Heker KH, Roux KH. High and low annealing temperatures increase both specificity and yield in TD and SD PCR. Bio Techniques 1996; 20: 478-85.
• 25 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
• 26 Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-62.
• 27 Eberhardt W, Beck KF, Pfeilschifter J. Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidney Int 2002; 61: 20-30.
• 28 Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58: 1174-85.
• 29 Katoh M, Egashira K, Mitsui T, Takeshita A, Narita H. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. J Cardiovasc Pharmacol 2000; 35: 932-6.
• 30 Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000; 32: 73-83.
• 31 Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18: 1771-9.
• 32 Erlich J, Fearns C, Mathison J, Ulevitch RJ, Mackman N. Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun 1999; 67: 2540-6.
• 33 Crossman DC, Carr DP, Tuddenham EG, Pearson JD, McVey JH. The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem 1990; 265: 9782-7.
• 34 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
• 35 ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 713-7.